Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;31(4):439-53.
doi: 10.1007/s00281-009-0178-z. Epub 2009 Sep 25.

The pathological spectrum of CNS inflammatory demyelinating diseases

Affiliations
Review

The pathological spectrum of CNS inflammatory demyelinating diseases

Wei Hu et al. Semin Immunopathol. 2009 Nov.

Abstract

Inflammatory demyelinating diseases of the central nervous system (CNS) occur throughout the world and are the leading cause of nontraumatic neurological disability in young adults. They represent a broad spectrum of disorders that vary in their clinical course, regional distribution, and pathology. However, there can be a considerable overlap between at least some of these disorders, leading to misdiagnoses or diagnostic uncertainty. Multiple sclerosis (MS), the most common inflammatory demyelinating CNS disease affecting approximately one million adults, shares the basic pathological hallmark of CNS inflammatory demyelination. Advances based on recent systematic clinicopathologic-serologic correlative approaches have led to novel insights with respect to the classification of this disorder, the pathologic substrate of disability, a better understanding of the underlying pathogenic mechanisms involved in lesion formation, as well as the clinical relevance of cortical demyelination and normal appearing white matter pathology. In addition to prototypic MS, these diseases include Marburg variant of acute MS, Balo's concentric sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis, and tumefactive MS. The last decade has seen a resurgence of interest in examining the lesions of these inflammatory demyelinating CNS disorders with newer and more sophisticated immunological and molecular tools. Herein, we review the clinicopathologic features of these CNS inflammatory demyelinating disorders and discuss recent advances in understanding their immunopathogenesis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Neuropathol Exp Neurol. 1950 Jul;9(3):219-49 - PubMed
    1. Brain. 1999 Jan;122 ( Pt 1):17-26 - PubMed
    1. Brain. 2007 Apr;130(Pt 4):1089-104 - PubMed
    1. Ann Neurol. 2004 Apr;55(4):458-68 - PubMed
    1. Adv Neurol. 2006;98:27-45 - PubMed

MeSH terms

LinkOut - more resources